# MOTS-c: Research Overview — Supernova Peptides > A literature summary of MOTS-c (mitochondrial-derived peptide), studied for AMPK activation, metabolic regulation, exercise-mimicry, and age-related physical decline in animal models. A 16-amino-acid peptide encoded in the mitochondrion's own DNA — a retrograde stress signal studied for metabolic regulation, skeletal muscle homeostasis, and physical performance across aging. ## The short version **MOTS-c** (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide — sequence MRWQEMGYIFYPRKLR — and it comes from an unusual place: not from the cell nucleus where most human genes live, but from the **mitochondrial genome**, specifically a short open reading frame within the 12S ribosomal RNA gene (MT-RNR1). It is highly conserved across mammalian species, suggesting it does something important. Its best-characterized action is activating AMPK (AMP-activated protein kinase), a master metabolic sensor, by disrupting the folate cycle and de novo purine biosynthesis. The downstream effects studied include improved glucose handling, insulin sensitivity in skeletal muscle, and antioxidant gene activation. In mice across several age groups, exogenous MOTS-c administration significantly enhanced physical performance — framing it as a potential *exercise mimetic* [11]. The honest caveat: every claim about MOTS-c improving metabolism, performance, or aging in humans rests on animal experiments and one human observational biomarker association. No human intervention trials have been completed. MOTS-c is a research chemical, not an approved medicine, and this page gives no dose and no medical advice. ## What it is MOTS-c is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded by a short open reading frame within MT-RNR1, the mitochondrial 12S rRNA gene. Its mitochondrial origin is significant: the vast majority of human proteins are encoded in the nuclear genome, so MOTS-c belongs to a rare class called *mitochondrial-derived peptides* (MDPs), which includes humanin and SHLP1-6. The peptide is highly conserved across mammals. Genotype matters: a pro-diabetogenic mtDNA variant (m.1382A>C) disrupts the MOTS-c reading frame and shows ancestry-dependent associations with type 2 diabetes risk, which is direct evidence that naturally occurring MOTS-c variation has metabolic consequences in humans. This also means effects are not expected to be uniform across all individuals or populations. ## How it works The primary mechanistic pathway identified for MOTS-c is **inhibition of the folate cycle and de novo purine biosynthesis**. Disrupting those reactions causes a rise in AICAR (an endogenous AMPK activator), which in turn activates AMPK — the cell's principal energy-sensing kinase. AMPK activation in skeletal muscle improves glucose uptake and insulin sensitivity; it also promotes mitochondrial biogenesis and fatty acid oxidation [10]. Under metabolic stress, MOTS-c translocates from the mitochondrion to the cell nucleus — the first demonstrated retrograde signaling by a mitochondrial-encoded peptide — where it regulates nuclear gene expression in an AMPK-dependent manner, including antioxidant-response-element (ARE) genes through interaction with NRF2 [12]. This nuclear role links MOTS-c directly to cellular stress adaptation and antioxidant defense programs. A 2024 study using cell-free assays identified casein kinase 2 (CK2) as a **direct molecular target** of MOTS-c — a concrete binding partner, not just a downstream effect [8]. Tissue-specific CK2 modulation (activation in muscle, suppression in adipose tissue) appears to underlie MOTS-c effects on skeletal muscle glucose uptake and atrophy prevention. CK2 identification was a meaningful mechanistic advance, moving the field from pathway inference to a direct molecular interaction. ## What the research shows **Direct molecular target.** A 2024 iScience study demonstrated that MOTS-c directly binds and activates CK2 in cell-free assays. Tissue-specific CK2 modulation in young, aged, high-fat-diet, and immobilized mice underlay both muscle glucose uptake and prevention of skeletal muscle atrophy [8]. **Human biomarker association.** In a prospective multicenter cohort of 94 chronic hemodialysis patients (median 26.5-month follow-up), circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), and adding MOTS-c improved risk-model discrimination (AUC from 0.727 to 0.743) [9]. This is the strongest human clinical-association data for MOTS-c, and it is an observational biomarker association — not an intervention trial. **Exercise mimicry across aging.** A 2021 Nature Communications study showed that exercise induces endogenous MOTS-c in skeletal muscle and circulation in mice, and that exogenous MOTS-c administration significantly enhanced physical performance in mice at 2, 12, and 22 months of age. In the oldest group (22-23.5 months), MOTS-c significantly increased treadmill running capacity (P=0.000002), grip strength, and gait [11]. This framed MOTS-c as an exercise-mimetic regulator of age-dependent physical decline, though the study is in mice. **Nuclear retrograde signaling.** In human and mouse cells (HEK293, fibroblasts), metabolic stress induced MOTS-c nuclear translocation and AMPK-dependent regulation of antioxidant and metabolic genes through NRF2 interaction [12]. This was the first demonstrated retrograde mitochondrion-to-nucleus signaling by a mitochondrial-encoded peptide. **Comprehensive mechanistic review.** A 2023 review in *Journal of Translational Medicine* synthesized MOTS-c biology across mechanism, model organisms, exercise, stress adaptation, metabolism, and aging pathways [10]. It remains the most current consolidated reference for the field. ## Reported effects, cautions & safety MOTS-c is a research-only compound with no approved human indication, and the absence of completed human intervention trials means there are no community anecdotal signals documented in this desk's source material. The cautions here derive from the cited literature and the regulatory record. Key cautions: - **No human efficacy trials.** Every claim about exogenous MOTS-c improving metabolism, performance, or aging derives from cell or animal studies — predominantly mice and rats. Human data are observational biomarker associations, not interventional outcomes [10]. - **No validated human pharmacokinetics.** There is no published, measured human half-life, bioavailability, or dose-response for MOTS-c. Rodent doses used in studies (0.5–15 mg/kg/day) cannot be extrapolated to humans. - **Research-chemical status.** MOTS-c is not approved by the FDA for any use. Product purity, identity, and sterility in commercial research-chemical supply vary and are not regulated as pharmaceuticals. - **Anti-doping prohibition.** MOTS-c is treated as a prohibited substance in elite sport by anti-doping bodies including USADA/WADA under hormone and metabolic modulator categories; athlete use can result in sanctions. - **Ancestry and genotype interactions.** The pro-diabetogenic m.1382A>C mtDNA variant and ancestry-dependent exercise responses in published data suggest effects are not uniform across populations. - **Evidence-claim gap.** Consumer interest in MOTS-c for fat loss, longevity, and performance greatly exceeds the strength of clinical evidence, creating a gap that this desk exists to contextualize. ## Where it fits in longevity research MOTS-c occupies a genuinely novel niche in aging biology: it is the only mitochondrial-encoded peptide with documented retrograde nuclear signaling, and it links exercise biology directly to the mitochondrial genome in a way that was not appreciated before 2015 [12]. Among the three compounds on this desk, it is the one most squarely addressing the *mitochondrial dysfunction* axis of aging — where Epitalon addresses telomeres and the neuroendocrine circadian axis, and NAD+ addresses the coenzyme substrate for sirtuin and PARP enzymes, MOTS-c is the mitochondrion's own stress-signal system. Its animal evidence is mechanistically coherent and increasingly well-supported, particularly with the CK2 binding result [8]. The gap — no human interventional data — is the honest boundary of what the science currently supports. See the [comparison page](/compare) for a direct side-by-side with the other two. ![MOTS-c mitochondrial peptide and AMPK energy-sensor pathway in cold indigo night palette](/images/mots-c.webp) --- An independent literature desk mapping the published science on geroprotective compounds — citations in evidence, judgment reserved.